Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure.
Previous studies have demonstrated that continuous infusion of furosemide results in increased diuresis and natriuresis compared with bolus administration of the drug in patients with severe heart failure. We reasoned that continuous infusion of furosemide caused less activation of neurohumoral mechanisms, since other studies have shown that bolus administration of furosemide may activate this system. We therefore tested the hypothesis that continuous administration of furosemide would increase water and sodium excretion due to less activation of neurohormones. Eight patients with severe heart failure were studied during continuous infusion over 24 h and bolus injections of furosemide twice daily in a randomized cross-over study. Bolus administration of furosemide increased diuresis and natriuresis significantly in the first 4 h after administration compared with continuous administration, but this was later reversed, resulting in similar 24 h total output. The neurohormones measured at baseline were all markedly elevated. Neither regimens of furosemide caused any further significant changes in neurohumoral response except that pro-ANF decreased more during the first 8 h after bolus administration compared to continuous infusion. This study has demonstrated that bolus administration of furosemide in conventional doses is equally effective as continuous intravenous infusion in patients with severe heart failure. This may be due to maximal neurohormonal activation in severe heart failure (NYHA III-IV) which could not be further activated by bolus administration.
Aaser
E
E
Medical Department B, Rikshospitalet University Hospital, Oslo, Norway.
Gullestad
L
L
Tølløfsrud
S
S
Lundberg
J
J
Hall
C
C
Djøseland
O
O
Kjekshus
J
J
Forfang
K
K
D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D002395:Catecholamines / Q000097:blood; D018592:Cross-Over Studies; D004231:Diuresis / Q000187:drug effects*; D004232:Diuretics / Q000008:administration & dosage*; D019332:Endothelin-1; D016232:Endothelins / Q000097:blood; D005260:Female; D005665:Furosemide / Q000008:administration & dosage*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D009478:Neuropeptide Y / Q000097:blood; D011498:Protein Precursors / Q000097:blood; D014667:Vasopressins / Q000097:blood
D002395:Catecholamines; D004232:Diuretics; D019332:Endothelin-1; D016232:Endothelins; D006728:Hormones; D009478:Neuropeptide Y; D011498:Protein Precursors; D014667:Vasopressins; D005665:Furosemide; D009320:Atrial Natriuretic Factor